股价表现 - Cardinal Health (CAH) 最近的股价为103.37美元，较前一交易日收盘价上涨了0.53%[1] - Cardinal Health 的股价在过去一个月下跌了7.37%，落后于医疗行业的5.82%和标普500指数的4.16%的跌幅[2] 财报预测 - 投资者将密切关注Cardinal Health在即将发布的财报中的表现。分析师预计公司将在2024年5月2日发布的财报中每股盈利1.95美元，同比增长12.07%。同时，最新的共识估计显示公司预计营收为558.2亿美元，同比增长10.56%[3] - 根据Zacks Consensus Estimates，Cardinal Health全年预计每股盈利7.28美元，营收为2269亿美元，同比增长分别为+25.73%和+10.68%。投资者应注意分析师对Cardinal Health的最新估计是否有任何修改[4] 估值和行业排名 - 在估值方面，Cardinal Health目前的前瞻市盈率为14.13，相比其行业平均前瞻市盈率17.53，表现出折价[8] - 需要进一步注意的是，CAH目前的PEG比率为0.99。PEG比率类似于常用的市盈率，但这一指标还考虑了公司预期的盈利增长率。医疗-牙科用品行业的平均PEG比率在昨日收盘时为1.79[9] - 医疗-牙科用品行业属于医疗行业。该行业目前的Zacks行业排名为74，位于所有250多个行业的前30%[10]

Cardinal Health (CAH) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this prescription drug distributor have returned -7.4%, compared to the Zacks S&P 500 composite's -4.2% change. During this period, the Zacks Medical - Dental Supplies industry, which Cardinal falls in, has lost 4.2%. The key question now is: What could be the stock's future direction?W ...

DUBLIN, Ohio, April 22, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35. Despite the nonrenewal of the OptumRx contracts, the company also reiterated both its Pharmaceutical and Specialty Solutions long-term segment profit CAGR target of 4% to 6% and its consolidated non-GAAP EPS CAGR ta ...

champpixs CAH is overvalued Cardinal Health (NYSE:CAH) caught our attention recently when we were screening for stocks with yields noticeably outside their normal range. And CAH really caught our attention because its dividend yield is currently way out of its historical range. As you can clearly see from the charts below, its current yield of 1.88% is among the lowest levels in at least 5 years. It is lower than its 5-year average yield of 3.25% by a whopping 42%, implying substantial overvaluation. Other ...

Cardinal Health (CAH) closed the most recent trading day at $107.03, moving +1.84% from the previous trading session. This move outpaced the S&P 500's daily loss of 1.2%. Meanwhile, the Dow experienced a drop of 0.65%, and the technology-dominated Nasdaq saw a decrease of 1.79%.The prescription drug distributor's stock has dropped by 4.98% in the past month, exceeding the Medical sector's loss of 6.57% and lagging the S&P 500's loss of 0.85%.Market participants will be closely following the financial result ...

Cardinal Health - CPI是用来衡量通货膨胀和通货紧缩率的指标[1] - CPI数据发布后，市场会有正面或负面的反应[2] - Cardinal Health是一家领先的医疗保健分销商，股价在过去一年上涨了33%[5] - Cardinal Health在2024财年第二季度报告中，总收入同比增长12%，净收入从负1.3亿美元增长到3.54亿美元[6] - CAH提高了2024全年的盈利预期，预计每股收益在7.20美元至7.35美元之间[7] Forestar Group - Forestar Group是一家专门从事住宅用地开发的房地产公司，股价在过去一年翻了一番[11] - Forestar在2024财年第一季度报告中，总收入增长了41%，净收入同比增长了84%[12] - Forestar预计2024全年收入将达到14亿至15亿美元，预计交付约1.5万个住宅用地[14] Blue Owl Capital - Blue Owl Capital是一家投资公司，股价在过去一年上涨了23%，提供9.59%的年度股息率[16] - Blue Owl Capital在2023财年第四季度报告中，总投资收入增长了14%，净收入同比略有下降[18]

Cardinal Health (CAH) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this prescription drug distributor have returned -3.2%, compared to the Zacks S&P 500 composite's +1.6% change. During this period, the Zacks Medical - Dental Supplies industry, which Cardinal falls in, has lost 0.4%. The key question now is: What could be the stock ...

股价表现 - Cardinal Health (CAH) 最近的股价为 $109.47，较前一个交易日下跌了 -0.41% [1] - Cardinal Health 过去一个月的股价下跌了 4.56%，落后于医疗行业的下跌幅度为 0.6% 和标普500指数的上涨幅度为 2.57% [2] 财务预测 - Cardinal Health 即将发布财报，预计每股收益为 $1.96，同比增长 12.64%，营收预计为 $55.82 亿美元，同比增长 10.56% [3][4] - Zacks Consensus Estimates 预计全年每股收益为 $7.28，营收为 $226.9 亿美元，同比增长分别为 +25.73% 和 +10.68% [5] 评级和指标 - Cardinal Health 的 Zacks Rank 为 2 (Buy)，显示分析师对公司的业务健康和盈利能力持乐观态度 [8] - Cardinal Health 目前的前瞻市盈率为 15.09，低于行业平均值 18.49 [9] - CAH 目前的 PEG 比率为 1.06，略低于医疗 - 牙科用品行业的平均 PEG 比率 1.8 [10] 行业排名 - 医疗 - 牙科用品行业属于医疗行业，目前的 Zacks Industry Rank 为 81，在 250 多个行业中排名前 33% [11] - Zacks Industry Rank 衡量了行业群体的实力，研究表明排名前 50% 的行业胜过后 50% 的行业 [12] 监控工具 - 使用 Zacks.com 监控所有这些影响股票的指标，以及更多信息 [13]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Cardinal Health (CAH) , which belongs to the Zacks Medical - Dental Supplies industry, could be a great candidate to consider.When looking at the last two reports, this prescription drug distributor has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 20.12%, on average, in the last two quarters.For the las ...

公司业务 - Cardinal Health Inc. (CAH)因其收购驱动的策略、多元化产品组合和强劲的制药业务而处于增长的有利位置[1] - CAH市值为271亿美元，是一家全国性的药品分销商和服务提供商，预计未来五年盈利将增长14.3%[2] - 公司于2023年12月宣布推出SmartGown EDGE Breathable Surgical Gown，以提供手术团队在手术室内安全便捷的仪器访问[4] - 公司于2023年9月宣布推出Kangaroo OMNI Enteral Feeding Pump，旨在为肠内喂养患者提供更多选择，满足其个性化需求[5] - 公司于2024年1月宣布已达成协议，以12亿美元现金收购Specialty Networks，这将为独立专科提供者和合作伙伴创造临床和经济价值[10] 市场表现 - 投资者对Cardinal Health的医疗和制药产品组合持乐观态度，这为公司在利基领域获得竞争优势[3] - 投资者对Cardinal Health在过去几个月在战略地区开设几家分销中心持乐观态度[6] - 公司于2023年12月宣布计划在南卡罗来纳州格林维尔建立新的分销中心，以支持其At-Home Solutions业务[7] - Cardinal Health Canada宣布计划在大多伦多地区开设新的分销中心，以更好地满足加拿大医疗和外科产品需求[8] - Cardinal Health继续面临支持销售的高成本和不断上升的运营费用，这可能在2024财年上半年对利润率造成影响[11] 财务展望 - Cardinal Health令人印象深刻的2024财年第二季度业绩增强了乐观情绪，公司的制药业务表现强劲[9] - Cardinal Health的Monoject注射器在FDA的不利建议下受到负面影响，可能引发担忧[12] - Zacks对2024财年Cardinal Health的营收预期为226.9亿美元，较上一年水平提高10.7%[13] - 股票分析师建议关注DaVita Inc. (DVA)、Stryker (SYK)和Cencora, Inc. (COR)等其他医疗领域的优秀股票[14]